Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.
Andrew Bateman(Mayo Clinic), Richard G. Vile(Mayo Clinic), Allan B. Dietz(Mayo Clinic), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Christine M. Lohse(Quantitative BioSciences), Michael J. Gough(Providence Portland Medical Center), Tim Kottke(Mayo Clinic in Arizona), Robert D. Simari(University of Kansas), Alan Melcher(University College Hospital), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Emmanouela Linardakis(Mayo Clinic in Arizona), Atique U. Ahmed(Northwestern University), David S. Riddle(Mayo Clinic in Arizona), Tim Peterson(Memorial Sloan Kettering Cancer Center)
PubMed
November 15, 2002
Cited by 112
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767